These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39005612)

  • 1. sFlt1/PlGF among patients with suspected preeclampsia when considering hypertensive status.
    Patel E; Suresh S; Mueller A; Bisson C; Zhu K; Verlohren S; von Dadelszen P; Magee L; Rana S
    AJOG Glob Rep; 2024 Aug; 4(3):100359. PubMed ID: 39005612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The additive role of angiogenic markers for women with confirmed preeclampsia.
    Suresh S; Patel E; Mueller A; Morgan J; Lewandowski WL; Verlohren S; von Dadelszen P; Magee LA; Rana S
    Am J Obstet Gynecol; 2023 May; 228(5):573.e1-573.e11. PubMed ID: 36356699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PP059. Angiogenic factors and risk of preeclampsia related adverse outcomes in twin pregnancies.
    Rana S; Hacker M; Merport A; Salahuddin S; Verlohren S; Perschel F; Karumanchi SA
    Pregnancy Hypertens; 2012 Jul; 2(3):273-4. PubMed ID: 26105382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
    Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
    Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of hypertensive disorders after screening at 36 weeks' gestation: comparison of angiogenic markers with competing-risks model.
    Schiattarella A; Magee LA; Wright A; Syngelaki A; Akolekar R; Von Dadelszen P; Nicolaides KH
    Ultrasound Obstet Gynecol; 2023 Sep; 62(3):345-352. PubMed ID: 37329494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders.
    Engels T; Pape J; Schoofs K; Henrich W; Verlohren S
    Hypertens Pregnancy; 2013 Nov; 32(4):459-73. PubMed ID: 23957293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of PlGF and the sFlt1/PlGF ratio in the management of hypertensive pregnancy disorders: A retrospective real-world study in China.
    Yang H; Guo F; Guo Q; Wang Y; He P; Zhang H; Wang S
    Clin Chim Acta; 2022 Mar; 528():90-97. PubMed ID: 35104464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.
    Rana S; Powe CE; Salahuddin S; Verlohren S; Perschel FH; Levine RJ; Lim KH; Wenger JB; Thadhani R; Karumanchi SA
    Circulation; 2012 Feb; 125(7):911-9. PubMed ID: 22261192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
    Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
    Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive value of the sFlt1/PlGF ratio for the diagnosis of preeclampsia in high-risk patients].
    Husse S; Gottschlich A; Schrey S; Stepan H; Hoffmann J
    Z Geburtshilfe Neonatol; 2014 Feb; 218(1):34-41. PubMed ID: 24595913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients.
    Lopes Perdigao J; Chinthala S; Mueller A; Minhas R; Ramadan H; Nasim R; Naseem H; Young D; Shahul S; Chan SL; Yeo KJ; Rana S
    Hypertension; 2019 Apr; 73(4):868-877. PubMed ID: 30798660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
    Frampton GK; Jones J; Rose M; Payne L
    Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.
    Chaiworapongsa T; Romero R; Savasan ZA; Kusanovic JP; Ogge G; Soto E; Dong Z; Tarca A; Gaurav B; Hassan SS
    J Matern Fetal Neonatal Med; 2011 Oct; 24(10):1187-207. PubMed ID: 21827221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.
    Sokratous N; Wright A; Syngelaki A; Kakouri E; Laich A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Jan; 63(1):88-97. PubMed ID: 37724582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension.
    Heimberger S; Mueller A; Ratnaparkhi R; Perdigao JL; Rana S
    Pregnancy Hypertens; 2020 Apr; 20():124-130. PubMed ID: 32299059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
    Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
    BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic biomarkers in triage and risk for preeclampsia with severe features.
    Rana S; Salahuddin S; Mueller A; Berg AH; Thadhani RI; Karumanchi SA
    Pregnancy Hypertens; 2018 Jul; 13():100-106. PubMed ID: 30177034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.
    Gaccioli F; Sovio U; Cook E; Hund M; Charnock-Jones DS; Smith GCS
    Lancet Child Adolesc Health; 2018 Aug; 2(8):569-581. PubMed ID: 30119716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.